The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

from Yahoo Finance https://ift.tt/306Bcg3

We can readily understand why investors are attracted to unprofitable companies. For example, Intra-Cellular Therapies…

from Yahoo Finance https://ift.tt/3084r1S

Goldman Sachs has a new target price for gold — and in a new note it raised concerns about the dollar as well. The post Goldman Sachs boosts gold price target, says the U.S. dollar's reserve status is at risk appeared first on The Block.

from Yahoo Finance https://ift.tt/2P5ktUe

TORONTO, July 28, 2020 /CNW/ – Argonaut Gold Inc. (TSX: AR) (the "Company", "Argonaut Gold" or "Argonaut") is pleased to announce drill results from Phase Two of its drill campaign specifically targeting high-grade mineralization below the proposed pit at its 100% owned Magino property in Ontario, Canada, including 6.

from Yahoo Finance https://ift.tt/3jNopqJ

(Bloomberg) — Wall Street analysts and specialists are weighing the possibility that Pfizer Inc. and BioNTech SE may file their Covid-19 vaccine candidate with regulators by October after the pair said a late-stage Covid-19 vaccine study kicked off on Monday evening.Pfizer rose Tuesday on the announcement with its German partner, just hours after similar news from Moderna Inc. With AstraZeneca Plc already in Phase 3, it’s a “three-horse race,” Jared Holz said from the Jefferies health-care trading desk. “The government involvement makes us think we could hear anecdotal reports of trial progress even before the interim data is available later in the year,” he wrote to clients.Holz expects at least one vaccine will get an emergency use authorization before November, which many have thought may give President Donald Trump a new foothold in the election as his polling numbers slip in favor of Democratic contender Joe Biden. But not everyone is as optimistic over an October timeline.UBS analyst Navin Jacob said Pfizer’s program may have a “slight edge” over Moderna, but a Centers for Disease Control adviser that Jacob spoke with cast doubts about the October target. Some on Wall Street also reflected surprise that the vaccine candidate Pfizer and BioNTech selected was not the same shot that investors had seen detailed data from.Pfizer rose as much as 2.7% on Tuesday after posting second-quarter earnings that topped estimates and increasing its sales forecast. UBS, Navin JacobJacob spoke to an expert from the CDC’s Advisory Committee on Immunization Practices, who said an autumn 2020 readout from a Phase 3 trial would be “a stretch” as the rate of new infections for patients in the trial would likely be too slow. He predicted an initial look at results was more likely to come in the first half of next year.Jacob said Pfizer’s international study may have an advantage over Moderna’s U.S. based study if the trial is in areas where Covid-19 is quickly spreading. He was also positive on the results seen so far which seem to indicate the BNT162 program “may have slightly better efficacy.”SVB Leerink, Geoffrey PorgesThe selection of BNT162b2, “though a clear possibility,” according to Porges, “was somewhat of a surprise given the companies shared detailed data for BNT162b1, which vaccinates against the receptor binding domain (RBD) of the spike protein.” He expects the decision was driven by potentially better immune responses in older adults.“All leading companies are now targeting the spike protein, highlighting correlated clinical risk and long-term market erosion risk,” Porges said. That concentration calls into question the long-term viability of a market for these vaccines, he said.Pfizer’s vaccine appears to be enrolling in hotspots amid state reopenings, “inclusion of all these sites could increase the speed for enrollment, as well as shorten the time for accumulating enough events.”Barclays, Carter Gould“We previously viewed recent BNT162b1 data as the most promising vaccine candidate to date, and b2 at least directionally appears to have a better profile,” though the analyst notes more details are needed.He expects further characterization of BNT162b2, as well as details on the recent $1.95 billion contract with the U.S., and EU efforts to secure access, to be discussed on Tuesday’s call.Pfizer’s call is set to start at 10 a.m. in New York.(Updates shares in fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/2BB5gXG

Miller Value Partners recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 47.02% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned 20.54% in the same quarter. You should check out Miller Value Partners' top […]

from Yahoo Finance https://ift.tt/3f7ZP0j

For us, stock picking is in large part the hunt for the truly magnificent stocks. But when you hold the right stock…

from Yahoo Finance https://ift.tt/306owG5

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks…

from Yahoo Finance https://ift.tt/3025hxf

The company, whose Chief Executive Officer Elon Musk has spoken against further government aid as Congress debates another round of stimulus, said that along with cost cuts, the benefits had offset almost all of its costs due to the idling of factories in this year’s lockdowns. Tesla’s only U.S. vehicle factory — in California, where most of its cars are produced — was shut down for some six weeks in the second quarter ended June after an initial standoff with local authorities. Reuters could not immediately verify which government assistance the company received and in what country.

from Yahoo Finance https://ift.tt/3g2VeO2

(Bloomberg) — Remington Outdoor Co. filed for bankruptcy for the second time in two years with plans to sell the 200-year-old maker of firearms.The company said reduced gun sales prevented it from making money even after restructuring its finances in its first bankruptcy. Remington had $437.5 million in sales last year, about half the business it did in 2016, according to court papers filed in Decatur, Alabama.The company owes various lenders more than $250 million, including a $12.5 million debt to Remington’s home town of Huntsville, Alabama, which put up a loan to help upgrade a manufacturing plant there.The Chapter 11 filing allows the company to keep operating while it devises plans to turn around the business and pay its creditors.Remington will continue its hunt for a buyer, which began months before seeking court protection from creditors. The company landed one potential offer for all of its assets, but the unnamed suitor delayed making a final decision after the deal became public, company chief executive Ken D’Arcy said in court papers. The Wall Street Journal reported that the company held talks with the Navajo Nation about a sale, but those discussions fell apart.D’Arcy said the company is continuing to talk to its unnamed potential buyer as well as others.Earlier FilingRemington went bankrupt before in February 2018. It was felled by too much debt and overstocked gun dealers, who were left with unsold weapons after the surprise loss of Hillary Clinton — an advocate of gun control — to Donald Trump in the 2016 election. Cerberus Capital Management had acquired Remington in 2007, and the firearms and ammunition giant accumulated nearly $1 billion in debt.It emerged from bankruptcy in May 2018, minus more than $775 million of debt, with ownership transferred to senior lenders. This time, Remington is heading back to court even as gun sales revive amid civil unrest in the U.S. The company said it couldn’t take advantage of increased demand because the pandemic disrupted its manufacturing.In the months leading up to its prior bankruptcy, the company had trouble attracting capital and potential buyers because of the controversy over arms sales. Family members of nine children and educators killed in the 2012 Sandy Hook Elementary School massacre sued Remington over its marketing of the semiautomatic military-style rifle the shooter used. A trial date was set for 2021.Remington said it continues to fight all the product liability lawsuits its faces.Advisers to Remington include lawyers at O’Melveny & Myers and Akin Gump Strauss Hauer & Feld, restructuring consultants at M-III Partners, and bankers at Ducera Partners, according to the petition.The case is Remington Outdoor Company Inc., 20-81688-11, U.S. Bankruptcy Court for the Northern District of Alabama.To view the docket in Bloomberg Law, click here.(Updates with details of sale efforts in the fifth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

from Yahoo Finance https://ift.tt/39Dr8hU